7 studies were found.

1.		Recruiting	XL119 Versus 5-Fluorouracil (5-FU) plus Leucovorin (LV) in Subjects with Advanced Biliary Tumors Condition: Biliary Tract Cancer
2.		Recruiting	Bortezomib as First-Line Systemic Therapy in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder Conditions: adult primary liver cancer; extrahepatic bile duct cancer; Gallbladder Cancer
3.		Recruiting	3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Biliary Duct or Gallbladder Cancer Conditions: unresectable extrahepatic bile duct cancer; recurrent gallbladder cancer; unresectable gallbladder cancer; recurrent extrahepatic bile duct cancer; ...
4.		Recruiting	Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer Conditions: adult primary liver cancer; extrahepatic bile duct cancer; Gallbladder Cancer; Pain
5.		Recruiting	Gemcitabine and Capecitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Gallbladder Cancer or Cholangiocarcinoma Conditions: extrahepatic bile duct cancer; Gallbladder Cancer
6.		Recruiting	BMS-247550 in Treating Patients With Liver or Gallbladder Cancer Conditions: adult primary liver cancer; extrahepatic bile duct cancer; Gallbladder Cancer
7.		Recruiting	Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer Conditions: adult primary liver cancer; cholangiocarcinoma of the extrahepatic bile duct; cholangiocarcinoma of the gallbladder; ...